Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Avoiding the immune rejection of transplanted T cells is central to the success of allogeneic cancer immunotherapies. One solution to protecting T-cell grafts from immune rejection involves the deletion of allogeneic factors and of factors that activate cytotoxic immune cells. Here we report the generation of hypoimmunogenic cancer-antigen-specific T cells derived from induced pluripotent stem cells (iPSCs) lacking β 2-microglobulin, the class-II major histocompatibility complex (MHC) transactivator and the natural killer (NK) cell-ligand poliovirus receptor CD155, and expressing single-chain MHC class-I antigen E. In mouse models of CD20-expressing leukaemia or lymphoma, differentiated T cells expressing a CD20 chimeric antigen receptor largely escaped recognition by NKG2A+ and DNAM-1+ NK cells and by CD8 and CD4 T cells in the allogeneic recipients while maintaining anti-tumour potency. Hypoimmunogenic iPSC-derived T cells may contribute to the creation of off-the-shelf T cell immunotherapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Scientists have also discovered that iPSCs can have improved immune escape by transducing the NK-inhibitory ligand-scHLA-E genes in addition to the knocking out of the reported HLA-I- and HLA-II-related genes and NK cell-activating ligand gene (B2M gene, CIITA gene and PVR gene, respectively) [118].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [118]
Citations
Cites
fastp: an ultra-fast all-in-one FASTQ preprocessor
Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty560 · Cited by 29,721
Lanier, L. L. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,769
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388 · cited 1×
“case of immunotherapies against cancer or infectious disease; and (3) no stimulation of host CD8 killer T cells and host CD4 helper T cells.”
BackgroundHLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
Braud, V. M., Allan, D. S. J., O'Callaghan, C. A., Söderström, K., D'Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., et al. (1998) · Nature · doi:10.1038/35869 · Cited by 2,227
A more efficient method to generate integration-free human iPS cells
Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K.-I., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1591 · Cited by 2,061
Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition
Ren, J., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1300 · Cited by 942
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2013 · Cited by 902
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O., Vogl, D. T., Lacey, S. F., Badros, A. Z., Garfall, A., Weiss, B., Finklestein, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3910 · Cited by 856 · cited 1×
“Owing to T cell ontogeny and the practical circumstances (limited usage of immunosuppressants) of their allogeneic use, therapies using T cells derived from iPSCs (iPS-T cells) or other PSCs should satisfy the following conditions, similar to therapies using primary allogeneic T cells: (1) sufficient effector function…”
BackgroundDeuse, T., Hu, X., Gravina, A., Wang, D., Tediashvili, G., De, C., Thayer, W. O., Wahl, A., Garcia, J. V., Reichenspurner, H., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0016-3 · Cited by 758
Research works printed but not linked: 1
- King, A. et al. HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells. Eur. J. Immunol. 30, 1623–1631 (2000). · doi:10.1002/1521-4141(200006)30:6<1623::aid-immu1623>3.0.co;2-m
Cited by
CAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 658
Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications
Cerneckis, J., Cai, H., & Shi, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01809-0 · Cited by 452
Chang, Y., Cai, X., Syahirah, R., Yao, Y., Xu, Y., Jin, G., Bhute, V. J., Torregrosa-Allen, S., Elzey, B. D., Won, Y.-Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37872-4 · Cited by 222
“While feasible approaches, such as engineering hypoimmunogenic universal donor hPSCs 58 – 61 and banking human leukocyte antigen (HLA)-homozygous hPSC libraries 62 , are readily available to avoid the potential risk of graft-versus-host disease (GvHD), preclinical animal models with an intact…”
Advances in Universal CAR-T Cell Therapy
Lin, H., Cheng, J., Mu, W., Zhou, J., & Zhu, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744823 · Cited by 199
“These hypoimmunogenic CAR-T cells largely escaped rejection by CD8T cells, CD4T cells, and NK cells, maintaining antitumor cytotoxicity (58).”
BackgroundForks in the road for CAR T and CAR NK cell cancer therapies
Dagher, O. K., & Posey, A. D. (2023) · Nature Immunology · doi:10.1038/s41590-023-01659-y · Cited by 172
“Sources of T cells for ex vivo expansion include peripheral blood and iPS cell-derived populations, with very few documented reports utilizing umbilical cord expanded T cells as these cells tend to be enriched in T reg cells after expansion 59,104,105 .”
Background
Metadata
- Authors
- Wang, B., Iriguchi, S., Waseda, M., Ueda, N., Ueda, T., Xu, H., Minagawa, A., Ishikawa, A., Yano, H., Ishi, T., Ito, R., Goto, M., Takahashi, R., Uemura, Y., Hotta, A., & Kaneko, S.
- Affiliations
- Kyoto University (JP)
- Central Institute for Experimental Animals (JP)
- National Cancer Center Hospital East (JP)
- Corresponding author
- Kaneko, Shin
- ORCID
- Venue
- Nature Biomedical Engineering
- Published
- 2021-05-17
- Volume
- 5
- Issue
- 5
- Pages
- 429-440
- ISSN
- 2157-846X (ISSN-L)
- OpenAlex
- W3160669634
- Cited by
- 189
- References
- 53
- Citations by year
- 2026: 29 · 2025: 31 · 2024: 60 · 2023: 51 · 2022: 13 · 2021: 5
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Biomedical Engineering (publishedVersion)
- PubMed (publishedVersion)
- Funders
- MEXT | Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- induced pluripotent stem cells, immune rejection, MHC class I, CD155, NKG2A, DNAM-1, natural killer cells, off-the-shelf T cell therapy, leukemia, lymphoma
- MeSH terms
- T Lineage-Specific Activation Antigen 1, Animals, Antigens, Differentiation, T-Lymphocyte, beta 2-Microglobulin, Cell Differentiation, Cell Line, Genetic Engineering, Humans, Leukemia, Lymphoma, Male, Receptors, Virus, T-Lymphocytes, Xenograft Model Antitumor Assays, Mice, NK Cell Lectin-Like Receptor Subfamily C, Gene Knockout Techniques, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. https://app.cochat.ai/papers/10.1038/s41551-021-00730-z
- The paper
- Wang, B., Iriguchi, S., Waseda, M., Ueda, N., Ueda, T., Xu, H., Minagawa, A., Ishikawa, A., Yano, H., Ishi, T., Ito, R., Goto, M., Takahashi, R., Uemura, Y., Hotta, A., & Kaneko, S. (2021). Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nature Biomedical Engineering. https://doi.org/10.1038/s41551-021-00730-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.